Drugs / NTLA-3001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06622668 | Nov 2024 → Jan 2025 | alpha 1-antitrypsin deficiency, lung disorder | Intellia Therapeutics | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | Intellia Therapeutics | Regulatory Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency intelliatx.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-30 | Intellia Therapeutics | Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency intelliatx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTLA-3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622668 ↗ |
| Route | Intravenous | “IV administration” NCT06622668 ↗ |